These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33857474)

  • 1. Protective efficacy of Hla-MntC-SACOL0723 fusion protein adjuvanted in alum and MPL against Staphylococcus aureus sepsis infection in mice.
    Ghaedi T; Davoodian P; Hassaniazad M; Eftekhar E; Faezi S; Abparvar AA; Einakian MA; Ahmadi K
    J Immunol Methods; 2021 Jul; 494():113055. PubMed ID: 33857474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monophosphoryl lipid A as a co-adjuvant in methicillin-resistant Staphylococcus aureus vaccine development: improvement of immune responses in a mouse model of infection.
    Mirshekar M; Haghighat S; Mousavi Z; Abdolghaffari AH; Yazdi MH
    Immunol Res; 2024 Jun; 72(3):490-502. PubMed ID: 38383811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant PBP2a of methicillin-resistant S. aureus formulation in Alum and Montanide ISA266 adjuvants induced cellular and humoral immune responses with protection in Balb/C mice.
    Mortazavi SS; Haghighat S; Mahdavi M
    Microb Pathog; 2020 Mar; 140():103945. PubMed ID: 31874228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immune response to a multi-epitope vaccine candidate in comparison with Hla
    Ahmadi K; Hasaniazad M; Habibi M; Ghaedi T; Kavousipour S; Nikbin VS; Kalani M; Faezi S
    Biologicals; 2021 Sep; 73():8-15. PubMed ID: 34376341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the immune responses to the HMS-based fusion protein and capsule-based conjugated molecules as vaccine candidates in a mouse model of Staphylococcus aureus systemic infection.
    Ahmadi K; Hasaniazad M; Kalani M; Faezi S; Ahmadi N; Enayatkhani M; Mahdavi M; Pouladfar G
    Microb Pathog; 2021 Jan; 150():104656. PubMed ID: 33253858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of Alum adjuvanted Amidase protein vaccine against Staphylococcus aureus infection in multiple mouse models.
    Suresh MK; Vasudevan AK; Biswas L; Biswas R
    J Appl Microbiol; 2022 Feb; 132(2):1422-1434. PubMed ID: 34487603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection.
    Hu DL; Narita K; Hyodo M; Hayakawa Y; Nakane A; Karaolis DK
    Vaccine; 2009 Jul; 27(35):4867-73. PubMed ID: 19406185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.
    Mancini F; Monaci E; Lofano G; Torre A; Bacconi M; Tavarini S; Sammicheli C; Arcidiacono L; Galletti B; Laera D; Pallaoro M; Tuscano G; Fontana MR; Bensi G; Grandi G; Rossi-Paccani S; Nuti S; Rappuoli R; De Gregorio E; Bagnoli F; Soldaini E; Bertholet S
    PLoS One; 2016; 11(1):e0147767. PubMed ID: 26812180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Staphylococcal Antigen-F (r-ScaF), a novel vaccine candidate against methicillin resistant Staphylococcus aureus infection: Potency and efficacy studies.
    Majelan PA; Mahdavi M; Yazdi MH; Salimi E; Pourmand MR
    Microb Pathog; 2019 Feb; 127():159-165. PubMed ID: 30521844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucomannan as a polysaccharide adjuvant improved immune responses against Staphylococcus aureus: Potency and efficacy studies.
    Dehnavi M; Haghighat S; Yazdi MH; Mahdavi M
    Microb Pathog; 2023 Mar; 176():106007. PubMed ID: 36709850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus.
    Ranjbariyan A; Haghighat S; Yazdi MH; Arbabi Bidgoli S
    World J Microbiol Biotechnol; 2022 Nov; 39(1):16. PubMed ID: 36401129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: Immunogenicity and protectivity.
    Haghighat S; Siadat SD; Rezayat Sorkhabadi SM; Akhavan Sepahi A; Sadat SM; Yazdi MH; Mahdavi M
    Microb Pathog; 2017 Jul; 108():32-39. PubMed ID: 28457901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.
    Sun H; Wei C; Liu B; Jing H; Feng Q; Tong Y; Yang Y; Yang L; Zuo Q; Zhang Y; Zou Q; Zeng H
    Int J Nanomedicine; 2015; 10():7275-90. PubMed ID: 26664118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope-based immunoinformatics study of a novel Hla-MntC-SACOL0723 fusion protein from Staphylococcus aureus: Induction of multi-pattern immune responses.
    Ahmadi K; Pouladfar G; Kalani M; Faezi S; Pourmand MR; Hasanzadeh S; Mafakher L; Aslani MM; Mahdavi M
    Mol Immunol; 2019 Oct; 114():88-99. PubMed ID: 31351414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia models.
    Yang L; Cai C; Feng Q; Shi Y; Zuo Q; Yang H; Jing H; Wei C; Zhuang Y; Zou Q; Zeng H
    Sci Rep; 2016 Feb; 6():20929. PubMed ID: 26865417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective humoral and CD4
    Yu W; Yao D; Yu S; Wang X; Li X; Wang M; Liu S; Feng Z; Chen X; Li W; Wang L; Liu W; Ma J; Yu L; Tong C; Song B; Cui Y
    Sci Rep; 2018 Feb; 8(1):3580. PubMed ID: 29483570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel recombinant vaccine candidate comprising PBP2a and autolysin against Methicillin Resistant Staphylococcus aureus confers protection in the experimental mice.
    Haghighat S; Siadat SD; Sorkhabadi SMR; Sepahi AA; Mahdavi M
    Mol Immunol; 2017 Nov; 91():1-7. PubMed ID: 28858628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
    Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
    Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of using a combination of staphylococcal superantigen-like proteins 3, 7 and 11 in a fusion vaccine for Staphylococcus aureus.
    Chan JYH; Clow F; Pearson V; Langley RJ; Fraser JD; Radcliff FJ
    Immunol Cell Biol; 2024; 102(5):365-380. PubMed ID: 38572664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.